Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2020 July;86(7) > Minerva Anestesiologica 2020 July;86(7):768-76

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

EXPERTS’ OPINION   Freefree

Minerva Anestesiologica 2020 July;86(7):768-76

DOI: 10.23736/S0375-9393.20.14169-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Presepsin as a biomarker in perioperative medicine

Jessica HANDKE 1, Ornella PIAZZA 2 , Jan LARMANN 1, Simonetta TESORO 3, Edoardo DE ROBERTIS 3

1 Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany; 2 Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy; 3 Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy



Presepsin is the soluble fragment of CD14, a multifunctional glycoprotein expressed on the surface of innate immune cells. In healthy individuals, presepsin is present in very low concentrations with reference values ranging from 60 to 382 pg/mL. Several studies have shown that presepsin is a valuable biomarker for sepsis diagnosis in adults. Only lately, presepsin has been evaluated for prediction and early detection of neonatal sepsis and septic shock. Elevated plasma presepsin concentration has also been reported in patients undergoing cardiac and non-cardiac surgery and it has further been evaluated as a potential independent predictor of perioperative cardiovascular complications and mortality. Combined cardiac and inflammatory biomarker evaluation may offer additive predictive information, but further investigations in large populations are required to determine presepsin diagnostic and prognostic value, in order to personalize therapy and reduce surgical patients’ morbidity and mortality.


KEY WORDS: Presepsin protein, human; Sepsis; Biomarkers

top of page